Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study

• Published in: American journal of Alzheimer's disease and other dementias 2020-01, Vol.35, p.1533317520904551-1533317520904551
• Main Authors: Wake, Taisei, Tabuchi, Hajime, Funaki, Kei, Ito, Daisuke, Yamagata, Bun, Yoshizaki, Takahito, Nakahara, Tadaki, Jinzaki, Masahiro, Yoshimasu, Haruo, Tanahashi, Iori, Shimazaki, Hiroumi, Mimura, Masaru
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - diagnosis; Amyloid beta-Peptides - metabolism; Anxiety - psychology; Cognitive Dysfunction - diagnostic imaging; Current Topics in Research; Depression - psychology; Disclosure; Female; Healthy Volunteers - statistics & numerical data; Humans; Longitudinal Studies; Male
• ISSN: 1533-3175; 1938-2731
• DOI: 10.1177/1533317520904551

This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.